Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 15/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.82 |
| ▸ | ADORA1 | P30542 | 8/20 | 0.72 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL938988 | 0.91 | ADORA2A (0.70) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL938991 | 0.91 | ADORA2A (0.70) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL938990 | 0.91 | ADORA2A (0.70) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL2297078 | 0.89 | ADORA2A (0.75) | ADORA2AADORA1ADORA2B | |
| SCHEMBL939603 | 0.87 | ADORA2A (0.69) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL939602 | 0.87 | ADORA2A (0.69) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL939601 | 0.87 | ADORA2A (0.69) | ADORA2AADORA3ADORA1ADORA2B | |
| SCHEMBL940871 | 0.86 | ADORA2A (0.81) | ADORA2AADORA1ADORA2B | |
| SCHEMBL940874 | 0.86 | ADORA2A (0.81) | ADORA2AADORA1ADORA2B | |
| SCHEMBL940872 | 0.86 | ADORA2A (0.81) | ADORA2AADORA1ADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100166698-A1 | NEW COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2010-07-01 | — | — | US | disclosed |
| US-20100166698-A1 | NEW COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2010-07-01 | — | — | US | disclosed |
| US-20070032450-A1 | New compositions and methods for the treatment of inflammation | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-02-08 | — | — | US | disclosed |
| US-20070032450-A1 | New compositions and methods for the treatment of inflammation | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2007-02-08 | — | — | US | disclosed |
| US-6514949-B1 | Administering A2A adenosine agonist in combination with an effective amount of a Type IV phosphodiesterase inhibitor for treatment of inflammation caused by an ischemia/reperfusion injury | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2003-02-04 | — | — | US | disclosed |
| US-6514949-B1 | Administering A2A adenosine agonist in combination with an effective amount of a Type IV phosphodiesterase inhibitor for treatment of inflammation caused by an ischemia/reperfusion injury | UNIVERSITY OF VIRGINIA PATENT FOUNDATION | 2003-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032450-A1 | New compositions and methods for the treatment of inflammation | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 4/4885 |
| US-20100166698-A1 | NEW COMPOSITIONS AND METHODS FOR THE TREATMENT OF INFLAMMATION | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA3 3/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.